Funding for this research was provided by:
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201603)
National Science &Technology Major Project “Key New Drug Creation and Manufacturing Program” (2015ZX09102017)
Received: 31 August 2018
Accepted: 25 December 2018
First Online: 14 January 2019
Ethics approval and consent to participate
: The study was approved by regulatory and independent ethics committees at Beijing Cancer Hospital and done in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent before study entry.
: All patients provided written informed consent for publication.
: Kai Wang and Jinwei Hu are employees of OrigiMed, Hai Wu, Hui Feng, and Sheng Yao are employees of Shanghai Junshi Biosciences Co. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.